Novel medicines approved in 2022 offer increased treatment options for patients

2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine approvals by the U.S. Food and Drug Administration (FDA). According to a new report released by the FDA’s Center for Drug Evaluation and Research (CDER), 37 novel medicines were approved by CDER last year. The Center for Biologics Evaluation and Research (CBER) also approved 8 new medicines in 2022 — including several gene therapies treating two rare blood disorders and a devastating neurodegenerative disease impacting young boys. Collectively, these newly-approved novel medicines offer the potential to expand treatment options for patients suffering from many debilitating and hard-to-treat diseases, resulting in improved survival, better health outcomes, enhanced quality of life — and in many cases, they provide a first-time treatment option for patients.